Introduction and Objective: Fibroblast growth factor 21 (FGF21) is a hepatokine with potential therapeutic relevance in diabetes, as it modulates glucose and lipid metabolism and suppresses sugar preference. However, depression, which is common in older adults, is associated with higher sucrose preference, especially in women, and its impact on FGF21’s metabolic effects remain unclear. We investigated whether depression modifies the relationship between FGF21 and sucrose intake in older adults.Methods: We analyzed 1,438 participants (845 women, aged 65-84) from the Bunkyo Health Study. Factors included body composition, dietary intake, and the Geriatric Depression Scale (GDS-15), with a GDS score of ≥5 indicating depressive tendencies. FGF21 responsiveness (iAUC-FGF21) was calculated from oral glucose tolerance test. Associations between FGF21 and sucrose intake were examined using sex-stratified multiple regression analyses. Participants were classified into four groups by depressive tendencies (no/present) and iAUC-FGF21 (high/low at median), and ANCOVA with Bonferroni post hoc test examined sucrose intake differences.Results: Women had higher sucrose intake (2.9% vs. 2.5%) and a higher prevalence of depressive tendencies (21.1% vs. 16.9%) than men. Only in women, sucrose intake positively correlated with GDS-15 levels (β=0.077, p=0.025) but negatively with iAUC-FGF21 (β=-0.119, p<0.001). In the four-group analysis among women, only those without depressive tendencies and with higher iAUC-FGF21 showed significantly lower sucrose intake (3.0±0.1%) compared to those with lower iAUC-FGF21 (3.3±0.1%, p=0.030).Conclusion: In older women, depressive tendencies were associated with increased sucrose intakes and appeared to attenuate FGF21’s suppressive effects on sucrose consumption, suggesting the need to consider mental health when evaluating FGF21’s potential in diabetes management.
S. Sakamoto: None. S. Kakehi: None. H. Kaga: None. H. Tabata: None. T. Tajima: None. H. Naito: None. T. Kogai: None. H. Watada: Speaker’s Bureau; Novo Nordisk, Boehringer-Ingelheim, Sumitomo Pharma, Eli Lilly and Company, Roche Diabetes Care, Merck Sharp & Dohme Corp, Sanwa Kagaku, Daiichi Sankyo. Research Support; Sumitomo Pharma, SBI Pharma, Kowa Company, Ltd, Sanwa Kagaku, Boehringer-Ingelheim. Speaker’s Bureau; Kyowa Kirin Co., Ltd, Bayer Pharmaceuticals, Inc, Abbott Japan Co., Ltd, Mitsubishi Tanabe Pharma Corporation. Y. Tamura: None.
Source link
Leave a Reply